|
業務類別
|
Biotechnology |
|
業務概覽
|
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML). |
| 公司地址
| 2 Corporate Drive, First Floor, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 239-2030 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.sentibio.com |
| 員工數量
| 39 |
| Dr. Timothy Lu, M.D.,PhD |
Chief Executive Officer, President and Director |
美元 618.76K |
27/03/2026 |
| Mr. Jay Cross |
Chief Financial Officer and Principal Accounting Officer |
-- |
27/03/2026 |
| Mr. Faraz Siddiqui |
Senior Vice President, Technical Operations |
-- |
25/02/2025 |
| Dr. Kanya Rajangam, M.D.,PhD |
President, Head of Research and Development and Chief Medical Officer |
美元 526.79K |
30/04/2025 |
|
|
| Dr. Brenda Cooperstone, M.D. |
Independent Director |
27/03/2026 |
| Dr. Timothy Lu, M.D.,PhD |
Chief Executive Officer, President and Director |
27/03/2026 |
| Dr. James J. Collins, PhD |
Independent Director |
27/03/2026 |
| Ms. Frances D. Schulz |
Independent Director |
27/03/2026 |
| Mr. Edward T. Mathers |
Independent Director |
27/03/2026 |
| Mr. Bryan Baum |
Director |
27/03/2026 |
| Mr. Donald Tang |
Director |
27/03/2026 |
| Mr. Feng Hsiung |
Director |
27/03/2026 |
|
|
|
|
